N-acetylcysteine versus placebo for treating nail biting, a double blind randomized placebo controlled clinical trial
- PMID: 23651231
- DOI: 10.2174/1871523011312030003
N-acetylcysteine versus placebo for treating nail biting, a double blind randomized placebo controlled clinical trial
Abstract
Nail biting is a common behavioral problem. While there are established behavioral interventions for management, they are of modest efficacy, and there is minimal evidence for effective pharmacotherapy. This study investigated the role of N-acetylcysteine (NAC) a potent glutathione and glutamate modulator for the treatment of pathological nail biting in children and adolescents. This pilot randomized, double-blind, placebo-controlled clinical trial of NAC (800 mg/day) or placebo enrolled 42 children and adolescents with chronic nail biting. Nail length was the objective outcome. Evaluations were carried out three times; before treatment, one month after enrollment in the study, and two months after enrollment. The duration (chronicity) of nail biting in the NAC and placebo groups was 3.63(2.45) and 5.09(3.74) years (P=0.14). The mean nail length gradually increased in both the NAC and placebo groups during this trial. There was a statistically significant difference between the two groups regarding increased nail length after the first month of trial [(5.21(5.75) and 1.18(3.02) millimeters], however no difference after two months was observed. Two patients in the NAC group discontinued medication due to adverse events. One patient experienced headache, agitation, and social withdrawal, and another patient expressed severe aggression after taking medication and was withdrawn from the study. This study supports the hypothesis that NAC decreases nail biting behavior in children and adolescents over the short term. NAC is relatively well tolerated and severe adverse effects are rare. However, there was a high rate of dropout. Further studies with longer durations that build on these preliminary data are recommended. This study is registered at the Iranian Registry of Clinical Trials (Irct registration number: IRCT201103023930N3).
Similar articles
-
A study protocol for the N-ICE trial: A randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine ("ice") dependence.Trials. 2019 Jun 4;20(1):325. doi: 10.1186/s13063-019-3450-0. Trials. 2019. PMID: 31164169 Free PMC article.
-
Nail-biting stuff? The effect of N-acetyl cysteine on nail-biting.CNS Spectr. 2009 Jul;14(7):357-60. doi: 10.1017/s1092852900023002. CNS Spectr. 2009. PMID: 19773711
-
A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder.Mol Autism. 2016 Apr 21;7:26. doi: 10.1186/s13229-016-0088-6. eCollection 2016. Mol Autism. 2016. PMID: 27103982 Free PMC article. Clinical Trial.
-
A review of N-acetylcysteine in the treatment of grooming disorders.Int J Dermatol. 2019 Apr;58(4):502-510. doi: 10.1111/ijd.14371. Epub 2019 Jan 22. Int J Dermatol. 2019. PMID: 30667049 Review.
-
Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: An Updated Systematic Review for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Sep. Report No.: 18-05239-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Sep. Report No.: 18-05239-EF-1. PMID: 30354042 Free Books & Documents. Review.
Cited by
-
Effects of N-acetylcysteine on oxidative stress biomarkers, depression, and anxiety symptoms in patients with multiple sclerosis.Neuropsychopharmacol Rep. 2023 Sep;43(3):382-390. doi: 10.1002/npr2.12360. Epub 2023 Jun 30. Neuropsychopharmacol Rep. 2023. PMID: 37386885 Free PMC article. Clinical Trial.
-
Pharmacological Interventions for Primary Psychodermatologic Disorders: An Evidence Mapping and Appraisal of Randomized Controlled Trials.J Cutan Med Surg. 2023 Mar-Apr;27(2):140-149. doi: 10.1177/12034754231155888. Epub 2023 Feb 20. J Cutan Med Surg. 2023. PMID: 36802832 Free PMC article. Review.
-
The Potential of N-Acetylcysteine for Treatment of Trichotillomania, Excoriation Disorder, Onychophagia, and Onychotillomania: An Updated Literature Review.Int J Environ Res Public Health. 2022 May 24;19(11):6370. doi: 10.3390/ijerph19116370. Int J Environ Res Public Health. 2022. PMID: 35681955 Free PMC article. Review.
-
Update on Diagnosis and Management of Onychophagia and Onychotillomania.Int J Environ Res Public Health. 2022 Mar 13;19(6):3392. doi: 10.3390/ijerph19063392. Int J Environ Res Public Health. 2022. PMID: 35329078 Free PMC article. Review.
-
Onychophagia as a clinical symptom: A pilot study of physicians and literature review.Sci Prog. 2021 Oct;104(4):368504211050288. doi: 10.1177/00368504211050288. Sci Prog. 2021. PMID: 34874802 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources